{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:06:58Z","timestamp":1781712418461,"version":"3.54.5"},"reference-count":103,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","archives-pmr.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Physical Medicine and Rehabilitation"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.apmr.2015.05.016","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T22:00:20Z","timestamp":1440712820000},"page":"S341-S357.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S","title":["Improving Outcomes in Patients With Refractory Idiopathic and Neurogenic Detrusor Overactivity: Management Strategies"],"prefix":"10.1016","volume":"96","author":[{"given":"David A.","family":"Ginsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne Kolton","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apmr.2015.05.016_bib1","unstructured":"International Continence Society. Terminology. Available at: http:\/\/www.ICS.org\/search\/defining-OAB. Accessed January 8,\u00a02015."},{"key":"10.1016\/j.apmr.2015.05.016_bib2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/nau.21003","article-title":"Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database","volume":"30","author":"Manack","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.apmr.2015.05.016_bib3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"issue":"5 Suppl 1","key":"10.1016\/j.apmr.2015.05.016_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0090-4295(02)01784-3","article-title":"Definition and epidemiology of overactive bladder","volume":"60","author":"Wein","year":"2002","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.apmr.2015.05.016_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pmr.2007.03.005","article-title":"Neurogenic bladder in spinal cord injury","volume":"18","author":"Samson","year":"2007","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"10.1016\/j.apmr.2015.05.016_bib6","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S0022-5347(17)32478-3","article-title":"Outcome of reflux in children with myelodysplasia managed by bladder pressure monitoring","volume":"152","author":"Flood","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11934-014-0433-2","article-title":"UTIs in patients with neurogenic bladder","volume":"15","author":"Jahromi","year":"2014","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.apmr.2015.05.016_bib8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ucl.2010.07.002","article-title":"Urologic complications of the neurogenic bladder","volume":"37","author":"Gormley","year":"2010","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.apmr.2015.05.016_bib9","series-title":"European Association of Urology. Guidelines on neurogenic lower urinary tract dysfunction","author":"Pannek","year":"2011"},{"key":"10.1016\/j.apmr.2015.05.016_bib10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/nur.21593","article-title":"A systematic review and meta-analysis of incontinence-associated dermatitis, incontinence, and moisture as risk factors for pressure ulcer development","volume":"37","author":"Beeckman","year":"2014","journal-title":"Res Nurs Health"},{"key":"10.1016\/j.apmr.2015.05.016_bib11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.12968\/jowc.2014.23.7.345","article-title":"From incontinence associated dermatitis to pressure ulcers","volume":"23","author":"Gefen","year":"2014","journal-title":"J Wound Care"},{"key":"10.1016\/j.apmr.2015.05.016_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1161\/01.STR.32.1.122","article-title":"Natural history and effects on 2-year outcomes of urinary incontinence after stroke","volume":"32","author":"Patel","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.apmr.2015.05.016_bib13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/01.STR.29.2.524","article-title":"Stroke and incontinence","volume":"29","author":"Brittain","year":"1998","journal-title":"Stroke"},{"key":"10.1016\/j.apmr.2015.05.016_bib14","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/jocn.12279","article-title":"Older people living at home: associations between falls and health complaints in men and women","volume":"22","author":"Hedman","year":"2013","journal-title":"J Clin Nurs"},{"key":"10.1016\/j.apmr.2015.05.016_bib15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s00103-014-1966-8","article-title":"[Falls in German hospitals and nursing homes 2006-2013. Frequencies, injuries, risk assessment, and preventive measures]","volume":"57","author":"Lahmann","year":"2014","journal-title":"Bundesgesundheitsblatt Gesundheitsofrschung Gesundheitsschutz"},{"key":"10.1016\/j.apmr.2015.05.016_bib16","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1017\/S1041610209990238","article-title":"Gender differences in predictors of nursing home placement in the elderly: a systematic review","volume":"21","author":"Luppa","year":"2009","journal-title":"Int Psychogeriatr"},{"issue":"Suppl 3","key":"10.1016\/j.apmr.2015.05.016_bib17","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/nau.22636","article-title":"Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder","volume":"33","author":"Haab","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.apmr.2015.05.016_bib18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1464-410X.2005.05889.x","article-title":"Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries","volume":"97","author":"Irwin","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.apmr.2015.05.016_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1471-2377-14-74","article-title":"Impact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity","volume":"14","author":"Tang","year":"2014","journal-title":"BMC Neurol"},{"key":"10.1016\/j.apmr.2015.05.016_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-7525-11-13","article-title":"Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review","volume":"11","author":"Tapia","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.apmr.2015.05.016_bib21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00005392-199907000-00020","article-title":"Urinary incontinence and depression","volume":"162","author":"Zorn","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib23","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0302-2838(02)00401-3","article-title":"A systematic review of the literature on the prevalence of sexual impairment in women with urinary incontinence and the prevalence of urinary leakage during sexual activity","volume":"42","author":"Shaw","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib24","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1046\/j.1532-5415.2001.49179.x","article-title":"Self-reported social and emotional impact of urinary incontinence","volume":"49","author":"Fultz","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.apmr.2015.05.016_bib25","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.eururo.2006.04.018","article-title":"The current and future burden and cost of overactive bladder in five European countries","volume":"50","author":"Reeves","year":"2006","journal-title":"Eur Urol"},{"issue":"4 Suppl","key":"10.1016\/j.apmr.2015.05.016_bib26","first-page":"S90","article-title":"The total economic burden of overactive bladder in the United States: a disease-specific approach","volume":"15","author":"Onukwugha","year":"2009","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.apmr.2015.05.016_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.18553\/jmcp.2014.20.2.130","article-title":"Economic burden of urgency urinary incontinence in the United States: a systematic review","volume":"20","author":"Coyne","year":"2014","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.apmr.2015.05.016_bib28","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0090-4295(03)00009-8","article-title":"Estimated economic costs of overactive bladder in the United States","volume":"61","author":"Hu","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.apmr.2015.05.016_bib29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.urology.2003.10.037","article-title":"Costs of urinary incontinence and overactive bladder in the United States: a comparative study","volume":"63","author":"Hu","year":"2004","journal-title":"Urology"},{"issue":"4 Suppl","key":"10.1016\/j.apmr.2015.05.016_bib30","first-page":"S101","article-title":"New perspectives on overactive bladder: quality of life impact, medication persistency, and treatment costs","volume":"11","author":"Mullins","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.apmr.2015.05.016_bib31","unstructured":"Chancellor MB. Part II: current treatment options for neurogenic bladder dysfunction. Renal & Neurology News. July 1, 2012. Available at: http:\/\/www.renalandurologynews.com\/part-ii-current-treatment-options-for-neurogenic-bladder-dysfunction\/article\/248201\/2\/. Accessed January 8,\u00a02015."},{"key":"10.1016\/j.apmr.2015.05.016_bib32","first-page":"182","article-title":"Overactive bladder: pharmacologic treatments in the neurogenic population","volume":"10","author":"Kennelly","year":"2008","journal-title":"Rev Urol"},{"issue":"Suppl 1","key":"10.1016\/j.apmr.2015.05.016_bib33","first-page":"1","article-title":"Consensus statement on neurogenic detrusor overactivity: multiple sclerosis and spinal cord injury","volume":"5","author":"Ellsworth","year":"2012","journal-title":"UroToday Intl J"},{"key":"10.1016\/j.apmr.2015.05.016_bib34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000353274","article-title":"Systematic review of the epidemiology of urinary incontinence and detrusor overactivity among patients with neurogenic overactive bladder","volume":"41","author":"Ruffion","year":"2013","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.apmr.2015.05.016_bib35","series-title":"Campbell-Welsh Urology","author":"Wein","year":"2012"},{"key":"10.1016\/j.apmr.2015.05.016_bib36","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/nau.22600","article-title":"Assessment of the urodynamic diagnosis in patients with urinary incontinence associated with normal pressure hydrocephalus","volume":"34","author":"Campos-Juanatey","year":"2015","journal-title":"Neurourol Urodyn"},{"issue":"Suppl 3","key":"10.1016\/j.apmr.2015.05.016_bib37","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.3949\/ccjm.74.Suppl_3.S21","article-title":"Overactive bladder: recognition requires vigilance for symptoms","volume":"74","author":"Rosenberg","year":"2007","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.apmr.2015.05.016_bib38","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/01.phm.0000219229.92056.c2","article-title":"Pharmacotherapy for neurogenic detrusor overactivity","volume":"85","author":"Chancellor","year":"2006","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.apmr.2015.05.016_bib39","unstructured":"Harrington A, Bhandary A. Neurogenic detrusor overactivity after spinal cord injury. Available at: http:\/\/www.rehabmedicine.pitt.edu\/docs\/RGR_PDFs\/RGR_8_11.pdf. Accessed December 19,\u00a02014."},{"key":"10.1016\/j.apmr.2015.05.016_bib40","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.apmr.2013.04.011","article-title":"Meta-analysis of botulinum toxin a detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury","volume":"94","author":"Mehta","year":"2011","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.apmr.2015.05.016_bib41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/nau.20870","article-title":"Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence","volume":"29","author":"Abrams","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.apmr.2015.05.016_bib42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2377-13-78","article-title":"Development of a short form and scoring algorithm from the validated actionable bladder symptom screening tool","volume":"13","author":"Bates","year":"2013","journal-title":"BMC Neurol"},{"key":"10.1016\/j.apmr.2015.05.016_bib43","unstructured":"Campea S. Autonomic dysreflexia in spinal cord injury. PM&R Knowledge NOW. Available at: http:\/\/me.aapmr.org\/kn\/article.html?id=2. Accessed January 8,\u00a02015."},{"key":"10.1016\/j.apmr.2015.05.016_bib44","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0090-4295(99)00553-1","article-title":"Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury","volume":"55","author":"Weld","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.apmr.2015.05.016_bib45","unstructured":"European Association of Urology (EAU); Lucas MG, Bedretdinova D, Bosch JLHR, et\u00a0al. Guidelines on urinary incontinence (2013). Available at: http:\/\/uroweb.org\/wp-content\/uploads\/20-Urinary-Incontinence_LR.pdf. Accessed December 19,\u00a02014."},{"issue":"6 Suppl","key":"10.1016\/j.apmr.2015.05.016_bib46","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline","volume":"188","author":"Gormley","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib47","series-title":"Bladder management for adults\u00a0with\u00a0spinal cord injury: a clinical practice guideline for health-care providers","year":"2006"},{"key":"10.1016\/j.apmr.2015.05.016_bib48","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/nau.20209","article-title":"Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study","volume":"25","author":"McClurg","year":"2006","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.apmr.2015.05.016_bib49","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ucl.2013.07.010","article-title":"Office-based behavioral therapy for management of incontinence and other pelvic disorders","volume":"40","author":"Newman","year":"2013","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.apmr.2015.05.016_bib50","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1442-2042.2008.02177.x","article-title":"Clinical guidelines for overactive bladder","volume":"16","author":"Yamaguchi","year":"2009","journal-title":"Int J Urol"},{"issue":"4","key":"10.1016\/j.apmr.2015.05.016_bib51","first-page":"CD003193","article-title":"Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults","author":"Alhasso","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.apmr.2015.05.016_bib52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/00003081-200403000-00010","article-title":"Nonsurgical treatment of urinary incontinence","volume":"47","author":"Borello-France","year":"2004","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.apmr.2015.05.016_bib53","first-page":"41","article-title":"Factors impacting self-care for urinary incontinence","volume":"26","author":"Milne","year":"2006","journal-title":"Urol Nurs"},{"key":"10.1016\/j.apmr.2015.05.016_bib54","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.eursup.2008.01.020","article-title":"Conservative treatment of patients with neurogenic bladder","volume":"7","author":"Wyndaele","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.apmr.2015.05.016_bib55","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/sc.2013.19","article-title":"Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics","volume":"51","author":"Madersbacher","year":"2013","journal-title":"Spinal Cord"},{"key":"10.1016\/j.apmr.2015.05.016_bib56","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/01.ju.0000103274.38694.b1","article-title":"Can higher doses of oxybutynin improve efficacy in neurogenic bladder?","volume":"171","author":"Bennett","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib57","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/10790268.2003.11753678","article-title":"Effect of controlled release oxybutynin on neurogenic bladder function in spinal cord injury","volume":"26","author":"O'Leary","year":"2003","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.apmr.2015.05.016_bib58","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1755-5949.2011.00248.x","article-title":"Anticholinergics for overactive bladder therapy: central nervous system effects","volume":"18","author":"Chancellor","year":"2012","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.apmr.2015.05.016_bib59","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1532-5415.2011.03473.x","article-title":"Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events?","volume":"59","author":"Paquette","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.apmr.2015.05.016_bib60","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1742-1241.2010.02449.x","article-title":"Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder","volume":"64","author":"Wagg","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.apmr.2015.05.016_bib61","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2013.01.002","article-title":"Randomised, multicenter, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study","volume":"64","author":"Wagg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib62","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/j.1532-5415.2005.00537.x","article-title":"Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients","volume":"53","author":"Kay","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.apmr.2015.05.016_bib63","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11934-013-0338-5","article-title":"Management of OAB in those over age 65","volume":"14","author":"Natalin","year":"2013","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.apmr.2015.05.016_bib64","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00345-014-1244-2","article-title":"Onset of action of the \u03b23-adrenoceptor agonist, mirabegron, in phase II and III clinical trials in patients with overactive bladder","volume":"32","author":"Chapple","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib65","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sc.2012.164","article-title":"Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion","volume":"51","author":"Krebs","year":"2013","journal-title":"Spinal Cord"},{"key":"10.1016\/j.apmr.2015.05.016_bib66","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1590\/S1677-55382009000100012","article-title":"Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder","volume":"35","author":"Tyagi","year":"2009","journal-title":"Int Braz J Urol"},{"issue":"5 Suppl 1","key":"10.1016\/j.apmr.2015.05.016_bib67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0090-4295(01)01635-1","article-title":"Beta3-adrenoceptors in human detrusor muscle","volume":"50","author":"Yamaguchi","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.apmr.2015.05.016_bib68","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.juro.2013.02.104","article-title":"Selective \u03b23-adrenoceptor agonists for the treatment of overactive bladder","volume":"190","author":"Andersson","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib69","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00005392-200101000-00071","article-title":"Relaxant effects of isoproterenol and selective beta3-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders","volume":"165","author":"Igawa","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib70","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/ijcp.12194","article-title":"Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomized, double-blind, placebo-controlled, phase III studies","volume":"67","author":"Nitti","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.apmr.2015.05.016_bib71","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib72","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00192-013-2161-4","article-title":"What do we know and not know about mirabegron, a novel \u03b23 agonist, in the treatment of overactive bladder?","volume":"25","author":"Caremel","year":"2014","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.apmr.2015.05.016_bib73","series-title":"Myrbetriq [prescribing information]","year":"2014"},{"key":"10.1016\/j.apmr.2015.05.016_bib74","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00192-012-1860-6","article-title":"Treatment of overactive bladder: what is on the horizon?","volume":"24","author":"Murphy","year":"2013","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.apmr.2015.05.016_bib75","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomized, double-blind, dose-ranging, phase 2 study (Symphony)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib76","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/nau.20733","article-title":"The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction","volume":"28","author":"Kabay","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.apmr.2015.05.016_bib77","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/nau.20958","article-title":"Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study","volume":"30","author":"de S\u00e8ze","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.apmr.2015.05.016_bib78","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000288223","article-title":"Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review","volume":"84","author":"Leong","year":"2010","journal-title":"Urol Int"},{"key":"10.1016\/j.apmr.2015.05.016_bib79","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1471-2490-14-65","article-title":"Protocol for a randomized, placebo-controlled, double-blind clinical trial investigating sacral neuromodulation for neurogenic lower urinary tract dysfunction","volume":"14","author":"Knupfer","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib80","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/nau.21009","article-title":"Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study","volume":"30","author":"Chaabane","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.apmr.2015.05.016_bib81","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1038\/sc.2014.157","article-title":"Sacral neuromodulation for neurogenic bladder and bowel dysfunction with multiple symptoms secondary to spinal cord disease","volume":"53","author":"Chen","year":"2015","journal-title":"Spinal Cord"},{"key":"10.1016\/j.apmr.2015.05.016_bib82","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/nau.20330","article-title":"In patients undergoing neuromodulation for intractable urge incontinence a reduction in 24-hr pad weight after the initial test stimulation best predicts long-term patient satisfaction","volume":"26","author":"Foster","year":"2007","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.apmr.2015.05.016_bib83","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1046\/j.1464-410X.2002.03028.x","article-title":"Long-term efficacy and safety results of the two-stage implantation technique in sacral neuromodulation","volume":"90","author":"Scheepens","year":"2002","journal-title":"BJU Int"},{"issue":"6 Suppl 1","key":"10.1016\/j.apmr.2015.05.016_bib84","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0090-4295(00)00597-5","article-title":"Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention","volume":"56","author":"Siegel","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.apmr.2015.05.016_bib85","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1179\/2045772313Y.0000000116","article-title":"Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state-of-the-art review","volume":"36","author":"Linsenmeyer","year":"2013","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.apmr.2015.05.016_bib86","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.annrmp.2008.03.003","article-title":"[Patient follow-up after botulinum toxin intradetrusor injection: proposal for management in neurogenic patients]","volume":"51","author":"de S\u00e8ze","year":"2008","journal-title":"Ann Readapt Med Phys"},{"key":"10.1016\/j.apmr.2015.05.016_bib87","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1756287213510962","article-title":"Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice","volume":"6","author":"Knuepfer","year":"2014","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib88","first-page":"1289","article-title":"Success rate and patients' satisfaction following intradetrusor disport injection in patients with detrusor overactivity: a comparative study of idiopathic and neurogenic types of detrusor overactivity","volume":"11","author":"Shakeri","year":"2014","journal-title":"Urol J"},{"key":"10.1016\/j.apmr.2015.05.016_bib89","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7224\/1537-2073.2012-031","article-title":"Advances in the management of neurogenic detrusor overactivity in multiple sclerosis","volume":"15","author":"Yonnet","year":"2013","journal-title":"Int J MS Care"},{"key":"10.1016\/j.apmr.2015.05.016_bib90","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib91","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib92","series-title":"BOTOX (onabotulinumtoxinA) [prescribing information]","year":"2013"},{"key":"10.1016\/j.apmr.2015.05.016_bib93","series-title":"DYSPORT (abotulinumtoxinA) [prescribing information]","year":"2009"},{"key":"10.1016\/j.apmr.2015.05.016_bib94","series-title":"IncobotulinumtoxinA (XEOMIN) [prescribing information]","year":"2014"},{"key":"10.1016\/j.apmr.2015.05.016_bib95","series-title":"RimabotulinumtoxinB (MYOBLOC) [prescribing information]","year":"2010"},{"key":"10.1016\/j.apmr.2015.05.016_bib96","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s12325-013-0054-z","article-title":"OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology","volume":"30","author":"Ginsberg","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.apmr.2015.05.016_bib97","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11255-009-9528-y","article-title":"Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity","volume":"41","author":"Ghalayini","year":"2009","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.apmr.2015.05.016_bib98","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s00391-013-0491-y","article-title":"Improving the health care of geriatric patients: management of urinary incontinence: a position paper","volume":"46","author":"Becher","year":"2013","journal-title":"Z Gerontol Geriatr"},{"key":"10.1016\/j.apmr.2015.05.016_bib99","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00381-013-2136-2","article-title":"Urodynamic studies in spinal cord tethering","volume":"29","author":"Kearns","year":"2013","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.apmr.2015.05.016_bib100","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.juro.2013.05.012","article-title":"Bladder and bowel dysfunction: evidence for multidisciplinary care","volume":"190","author":"Wolfe-Christensen","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.apmr.2015.05.016_bib101","first-page":"1423","article-title":"Effective physician-patient communication and health outcomes: a review","volume":"152","author":"Stewart","year":"1995","journal-title":"Can Med J"},{"issue":"4 Suppl","key":"10.1016\/j.apmr.2015.05.016_bib102","first-page":"A118","article-title":"Challenges for managing overactive bladder and guidance for patient support","volume":"15","author":"Schabert","year":"2009","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.apmr.2015.05.016_bib103","series-title":"Gablofen (baclofen injection) [prescribing information]","year":"2013"}],"container-title":["Archives of Physical Medicine and Rehabilitation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003999315004487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003999315004487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T19:33:06Z","timestamp":1617305586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003999315004487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":103,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0003999315004487"],"URL":"https:\/\/doi.org\/10.1016\/j.apmr.2015.05.016","relation":{},"ISSN":["0003-9993"],"issn-type":[{"value":"0003-9993","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving Outcomes in Patients With Refractory Idiopathic and Neurogenic Detrusor Overactivity: Management Strategies","name":"articletitle","label":"Article Title"},{"value":"Archives of Physical Medicine and Rehabilitation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apmr.2015.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}